FDA compounding panel recommends six peptides, including BPC-157, over staff objections
A federal advisory panel endorsed six peptides for compounding, but none is FDA-approved and nothing changes for patients until FDA finishes a rulemaking with no deadline.
An FDA advisory committee voted on July 23 and 24, 2026, to recommend that six peptides — BPC-157, KPV, TB-500, MOTS-c, semax and epitalon — go on the 503A Bulks List, the roster of ingredients compounding pharmacies may use. The panel's position ran against the written advice of FDA scientists, who had argued against adding any of the seven substances it reviewed [1][2].
The margins were thin. On July 23, the committee backed BPC-157, KPV and TB-500 by a vote of 8-6 with one abstention, and MOTS-c by 7-5 with two abstentions [1]. Semax and epitalon won approval on July 24 by similar margins [1]. Emideltide, also called delta sleep-inducing peptide, lost 7-6 with one abstention and was the only substance the panel turned down [1]. People in the room reported an audible gasp when the first tally was read, since the committee had rarely if ever defied FDA staff's written conclusions [1].
The votes do not change the law. No peptide was added to the 503A Bulks List, and none of the six is an FDA-approved drug [1]. Advisory committees recommend; FDA decides, and the agency is not obligated to follow the panel [2]. Scott Brunner, chief executive of the Alliance for Pharmacy Compounding, said FDA still has to formally adopt the advisers' position before pharmacies may lawfully compound the peptides [1].
FDA reviewers told the committee the evidence was too thin. Their briefing materials described the available studies, among them five trials of BPC-157, as too brief and too small to establish safety or effectiveness for the uses proposed, which included ulcerative colitis, wound healing, obesity, osteoporosis and opioid withdrawal [1]. Staff also raised questions about how well the substances can be characterized, their purity, their potential to trigger immune reactions and the limits of the clinical data [2].
The reconstituted panel drew criticism for counting more clinicians and business-connected members among its ranks than past versions did [1]. BPC-157 and TB-500 are classified as doping substances by international sports authorities and are widely sold online under "research use only" disclaimers despite FDA restrictions dating to 2023 [1].
Why it matters for patients
For anyone weighing these peptides, the practical picture is unchanged for now: they are not approved medicines, and they cannot legally be compounded while the rulemaking process plays out [1][2]. Compounded products generally sit outside standard pharmacy benefits, so patients would most likely keep paying cash even if a final rule eventually permits the ingredients [1].
Health plans and systems are being told to expect continued use of peptides bought from unregulated online sellers, and to focus on reviewing what patients are already taking and watching for side effects, given how little human safety data FDA's reviewers identified [1]. None of the seven substances under review is a GLP-1 medicine, and the meeting did not alter the status of semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound) or orforglipron (Foundayo) [1].
What happens next
FDA now decides whether to accept the panel's advice. If it does, adding substances to the 503A Bulks List calls for notice-and-comment rulemaking, and no statutory deadline drives the pace [2]. A prior round shows how long that can take: FDA proposed listing ten bulk substances in December 2016 and finished the rule in February 2019, placing six on the list and leaving four off [2].
FDA also changed its interim policy in January 2025, so substances first nominated on or after January 7 of that year no longer receive Category 1, 2 or 3 labels, and a favorable panel vote does not by itself grant enforcement discretion [2]. Health and Human Services Secretary Robert F. Kennedy Jr., who has described himself as "a big fan" of peptides, could try to speed the process up, but experts say the next steps and their timing remain unclear [1]. Lawyers following the issue caution that a long delay can be nearly as consequential for compounders as a rejection [2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.